Business

A Major Drug Middleman Just Agreed to Stop Inflating Prescription Prices After an FTC Lawsuit

By Mike Harper · July 28, 2026

The middleman between your doctor and your pharmacy just got caught inflating what you pay — and the FTC says the fix could save consumers billions.

CVS Caremark, one of the three largest pharmacy benefit managers in the country, agreed to a settlement with the Federal Trade Commission that the agency says could deliver up to $8.5 billion in consumer savings over the next decade, with an additional $4.5 billion in savings from point-of-sale rebates passed directly to patients.

The settlement resolves the FTC’s antitrust lawsuit alleging that Caremark, along with rival PBMs Express Scripts and OptumRx, artificially inflated the list prices of drugs — especially insulin — by running a system that rewarded them for keeping prices high. The FTC said the three companies forced drug manufacturers to compete for preferred coverage based on the size of rebates off inflated list prices rather than actual net costs. The PBMs pocketed the difference. Patients paid copays and coinsurance calculated from those same inflated numbers.

“This settlement brings billions in real savings to consumers feeling the pinch from excessive prescription drug prices.” FTC Chairman Andrew Ferguson said.

Under the terms, Caremark must delink its fees from drug list prices, increase transparency in its pricing, and give retail community pharmacies the option to shift to a cost-plus reimbursement model — meaning pharmacies would be paid based on what a drug actually costs rather than an opaque formula driven by rebate negotiations.

The deal also addresses concerns that Caremark interfered with independent hub pharmacies that help patients find the lowest out-of-pocket price. A January 2026 House Judiciary Committee staff report had documented how CVS allegedly used its market position to block innovation and competition.

This is the second PBM settlement the FTC has secured this year. In February, Express Scripts agreed to similar reforms in a deal the agency estimated would save consumers up to $7 billion over 10 years. A third case, against OptumRx, is still pending.

The three companies collectively process prescriptions for more than 200 million Americans. For years, the system they built was invisible to the people paying for it — patients who showed up at the pharmacy counter, saw a price, and had no way to know whether it reflected a drug’s actual cost or an inflated figure designed to maximize PBM revenue.

The Caremark settlement doesn’t put money directly in anyone’s pocket tomorrow. There’s no claim form to file. But the structural changes — delinking fees from list prices, requiring transparency, and giving pharmacies cost-plus options — are designed to bring down what consumers see at the register over the next decade. The question is whether those savings materialize at the scale the FTC projects, or whether the industry finds new ways to keep the spread.